CF PharmTech completes HK$0.65 million H-share buyback, treasury stock rises to 819,500 shares

Bulletin Express05-19

CF PharmTech, Inc. reported the repurchase of 32,000 H-shares on 19 May 2026 via on-market transactions on the Hong Kong Stock Exchange. The shares were bought at prices between HK$20.12 and HK$20.80, with a volume-weighted average cost of HK$20.36, bringing the cash outlay to approximately HK$0.65 million.

Following the transaction, the number of issued shares (excluding treasury shares) fell from 301,436,086 to 301,404,086, a marginal reduction of 0.0106%. Treasury shares increased to 819,500, while the total issued share count remained unchanged at 302,223,586, as the repurchased shares are being held in treasury rather than cancelled.

The buyback forms part of a repurchase mandate approved on 16 December 2025, which authorises the company to buy back up to 30,222,358 shares. Cumulative repurchases under this mandate now stand at 819,500 shares, representing 0.2712% of the issued share capital on the mandate date. In accordance with Hong Kong listing rules, CF PharmTech is subject to a moratorium on issuing new shares or disposing of treasury shares until 18 June 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment